IMPACT OF IMPLANT INFECTION TYRX NEURO Absorbable Antibacterial Envelope

Consequences of Implantable Device Infection on Patients and the Healthcare System

Both the TYRXTM Neuro Absorbable Antibacterial Envelope and the TYRXTM Cardiac Absorbable Antibacterial Envelope for cardiac implantable electronic devices (CIEDs) are designed to help reduce infection, and they share many of the same features. 

Cardiac implant research shows that despite efforts to take precautions and reduce risks, infection after implanting a CIED is a real possibility. When CIED infection does occur, the risk to the patient and the costs to the healthcare system are substantial.1-3

Cardiac infections typically cost the facility an average of ~$52,0004 but may exceed well over $100,000.3


Mortality significantly increased following CIED infections. Studies show a ~50% mortality rate at three years in patients who had a CIED infection.1

CIED Infections Are Costly

An infection may cost a facility $52,000 on average, but may exceed $100,000 depending on the infection’s severity.

CIED infection rates affect Centers for Medicaid and Medicare Services (CMS) reimbursement.4 As of October 1, 2012, the CMS has reduced payments to hospitals when a patient undergoing a CIED procedure acquires an infection during their hospital stay.4


The TYRX™ Neuro Absorbable Antibacterial Envelope may help reduce infection; studies show a 70% to 100% reduction of infection in high-risk patients in a cardiac application.

Economic Impact of CIED Infection1-3

A clinical and economic analysis (U.S. data) shows the projected savings of utilizing the TYRX Absorbable Antibacterial Envelope per patient.

Mittal S et al. Heart Rhythm. 2014;11(4):595-601.


Henrikson CA et al. JACC EP.2017;3(10):1158-1167.


Sohail MR et al. Arch Intern Med. 2011;171(20):1821-1828.


Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services Inpatient Prospective Payment System (IPPS) Final Rule FY13.